Secondly, we argue that although numerous CML antigens exist that would not be present in leukemia-derived DC, BCR-ABL, which is present, is known to be clinically relevant based on responses observed in patients immunized with BCR-ABL-derived peptides [17,87]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.